Cell, Not Sell: Be in Biotech in 2018


It's been a tale of two biotechs this year, with large cap stocks largely trailing their smaller peers, and the iShares Nasdaq Biotechnology ETF trailing the SPDR S&P Biotech ETF , which, as an equal-weighted fund, is skewed toward smaller companies. Some analysts see the pain for large cap biotechs continuing, and Jefferies' Michael Yee and his team believe that while biotech in general is a good place to invest next year, the bigger names could have a bit of a tougher go of things--although they could still make headway.



from Biotech News